Biotech Values

[DewDiligence]

…I have always been puzzled as to why MNTA/Wheeler decided to pursue M118 in the first place without a designated partner from the beginning.

As rkrw said, MNTA’s decision to develop M118 goes back a long way and predates Craig Wheeler’s 2006 hiring by several years.

When the M118 program was started, MNTA had not even submitted the Lovenox ANDA and management surely expected the FDA to approve Lovenox in less than the five years it ended up taking. Consequently, the cost of the M118 development program was not seen at the time as an unduly onerous financial burden.